Genesis Therapeutics Secures $200 Million for AI-Powered Drug Discovery
Exciting news is on the horizon as Genesis Therapeutics, a pioneering company harnessing the power of artificial intelligence for groundbreaking medicines, has just wrapped up an impressive Series B funding round, raising a whopping $200 million. This latest influx of funds catapults Genesis’ total funding to over $280 million, setting the stage for some remarkable advancements.
The investment journey was co-led by an unnamed U.S.-based life-sciences-focused investor and Andreessen Horowitz’s (a16z) Bio + Health, which had previously been at the forefront of the company’s early financing. Notably, this funding extravaganza also saw enthusiastic participation from the likes of Fidelity Management & Research Company, BlackRock, and NVIDIA’s venture capital arm, NVentures. Existing supporters of T. Rowe Price Associates, Rock Springs Capital, Radical Ventures, and Menlo Ventures also joined the party.
Genesis Therapeutics, headquartered in Burlingame, CA, with a bustling laboratory in San Diego, is the mastermind behind the remarkable AI platform known as GEMS (Genesis Exploration of Molecular Space). This ingenious platform artfully combines the magic of deep learning-based predictive models, sophisticated molecular simulations, and language models armed with chemical know-how. The result? An accelerated and optimized process for uncovering those elusive small molecule drug compounds.
But what truly sets Genesis apart from the pack is GEMS’ exceptional knack for taking on those tough, previously deemed “undruggable” targets. By seamlessly integrating physics-based computational chemistry with its in-house machine-learning engine, Genesis crafts foundational 3D models to examine how proteins and compounds interact. It’s a unique approach that’s making waves in a crowded field.
Genesis Therapeutics is no newcomer to big collaborations, having already teamed up with heavyweights like Genentech and Eli Lilly. With its AI-boosted drug candidates making strides toward clinical trials, this fresh infusion of funding is set to fuel the company’s journey to new heights. The focus? Pushing the envelope in clinical development, expanding the drug discovery pipeline, and striving to revolutionize the very essence of drug discovery through AI.
The remarkable funding milestone is a testament to Genesis’ dedication to transforming drug discovery with the power of AI. As the company forges ahead to deliver groundbreaking therapies to patients grappling with severe medical needs, it’s poised to make a real and lasting impact on the world of healthcare.
You can visit Genesis’ Official Website Here.
You can also read about 123milhas Suspension.
[…] You can also read about Genesis Therapeutics. […]